The Effect of Higher Level Computerized Clinical Decision Support Systems on Oncology Care: A Systematic Review

Sosse E. Klarenbeek 1,*,†, Harm H.A. Weekenstroo 1,*,†, J.P. Michiel Sedelaar 2, Jurgen J. Fütterer 1, Mathias Prokop 1 and Marcia Tummers 3

1 Department of Radiology, Nuclear Medicine and Anatomy, Radboud Institute for Health Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
2 Department of Urology, Radboud Institute for Health Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
3 Department for Health Evidence, Radboud Institute for Health Sciences, Radboud University Medical Center, 6500 HB Nijmegen, The Netherlands
* Correspondence: sosse.klarenbeek@radboudumc.nl (S.E.K.); harm.weekenstroo@radboudumc.nl (H.H.A.W.);
Tel.: +31-24-361-87-66 (S.E.K. & H.H.A.W.); Fax: +31-24-354-08-66 (S.E.K. & H.H.A.W.)
† Both authors contributed equally.

Received: 31 March 2020; Accepted: 18 April 2020; Published: 22 April 2020

Abstract: Background: To deal with complexity in cancer care, computerized clinical decision support systems (CDSSs) are developed to support quality of care and improve decision-making. We performed a systematic review to explore the value of CDSSs using automated clinical guidelines, Artificial Intelligence, datamining or statistical methods (higher level CDSSs) on the quality of care in oncology. Materials and Methods: The search strategy combined synonyms for ‘CDSS’ and ‘cancer.’ Pubmed, Embase, The Cochrane Library, Institute of Electrical and Electronics Engineers, Association of Computing Machinery digital library and Web of Science were systematically searched from January 2000 to December 2019. Included studies evaluated the impact of higher level CDSSs on process outcomes, guideline adherence and clinical outcomes. Results: 11,397 studies were selected for screening, after which 61 full-text articles were assessed for eligibility. Finally, nine studies were included in the final analysis with a total population size of 7985 patients. Types of cancer included breast cancer (63.1%), lung cancer (27.8%), prostate cancer (4.1%), colorectal cancer (3.1%) and other cancer types (1.9%). The included studies demonstrated significant improvements of higher level CDSSs on process outcomes and guideline adherence across diverse settings in oncology. No significant differences were reported for clinical outcomes. Conclusion: Higher level CDSSs seem to improve process outcomes and guidelines adherence but not clinical outcomes. It should be noticed that the included studies primarily focused on breast and lung cancer. To further explore the impact of higher level CDSSs on quality of care, high-quality research is required.

Keywords: clinical decision support system; neoplasm; systematic review; implementation; evidence-based medicine

1. Introduction

With annually >20 million new cancer cases expected worldwide by 2025, cancer is a major health problem [1]. Aging of populations in most economically developed countries challenges care by increasing the cancer rate and multimorbidity [2]. Consequently, new diagnostic and therapeutic options for cancer care are developed, tested and implemented at an accelerated pace [3]. Reading and appropriately weighing these options while incorporating patient characteristics has become a task of...
increasing difficulty for most clinicians [3]. As a result, decision-making based on clinicians’ personal experience and preference takes precedence, resulting in an unwanted variability in quality of care [4].

In response to this growing complexity in cancer care, computerized clinical decision support systems (CDSSs) are developed. These systems aim to support high quality of care and improve decision-making [5,6]. Usually, the basis of these knowledge systems is formed by combining information obtained from electronic health records (EHR) with clinical practice guidelines. Following the article of O’Sullivan et al., CDSSs can be distinguished in simple, mid- and complex level systems [7]. He defines simple level CDSSs as CDSSs that are usually embedded in order entry systems and verify whether the input provided by a clinician is allowable or within a specified range. The output of the CDSS is often an alert or reminder. Mid-level CDSSs comprise of prognostic calculators and automated clinical guideline systems, whereas complex level CDSSs use artificial intelligence, data mining or statistical methods to generate patient specific recommendations [7]. In this review we will focus on mid- and complex level systems as described by O’Sullivan et al., using the term higher level CDSSs.

Despite identification of factors that contributed to the success of CDSSs in clinical healthcare by several reviews in the past years [8–10], little is known about the impact of CDSSs on quality of care in oncology. A review of Pawloski et al. suggested that these systems positively impact the quality of cancer care delivered [11]. However, looking at the definitions used by O’Sullivan et al. [7], the CDSSs included in this review could be interpreted as simple level systems. To expand to this work, we performed a systematic review to explore the impact of higher level CDSSs on quality of care in oncology, operationalized in terms of process outcomes, guideline adherence and clinical outcomes.

2. Materials and Methods

2.1. Protocol and Registration

The protocol for this systematic review is registered in the PROSPERO database (CRD42019124800) [12].

2.2. Literature Search

To evaluate the impact of higher level CDSSs on quality of oncology care, we performed a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta Analysis Protocols 2015 (PRISMA-P 2015) [13]. A librarian was consulted for the search strategy; the conducted search combinations are shown in Supplementary File 1. The search strategy combined synonyms for ‘CDSS’ and ‘cancer.’ Pubmed, Embase, The Cochrane Library, Institute of Electrical and Electronics Engineers (IEEE), Association of Computing Machinery (ACM) digital library and Web of Science were systematically searched. Time limits were from January 1, 2000 to December 31, 2019. In addition, reference lists of systematic reviews identified during screening on title and abstract were searched for relevant papers [14–20].

2.3. Data Collection

The retrieved articles were imported into EndNote and duplicates were removed. First, titles and abstracts of articles resulting from the search strings were screened independently by two researchers (S.K. and H.W.). Studies meeting the inclusion criteria, as stated below, were selected for full text screening. Second, the full text papers were retrieved and reviewed (S.K. and H.W.). After the screening process, the inter-rater agreement was calculated. Any disparities were discussed at regular intervals and resolved via consensus. If required, a third reviewer was consulted to resolve disagreement (M.T.). The web-based software Rayyan was used throughout the process [21].

2.4. Study Selection Criteria

CDSSs considered relevant for this review included higher level systems. This are mid- and complex level as defined by O’Sullivan et al. [7]. Systems others than mid- and complex level were
excluded. Furthermore, only CDSSs applied in cancer care or cancer related treatments were considered. CDSSs in a pre-clinical stage were excluded; this was defined by use of the Technology Readiness Level (TRL) analyses and stated as a TRL < 7 [22]. Studies assessing process outcomes, guideline adherence and clinical outcomes were included. Process outcomes are defined as outcomes related to workflow, workload and costs. Adherence to guidelines denotes the degree of compliance between clinicians’ decision or action and the recommendation of clinical guidelines. Clinical outcomes are measurable changes in patients’ health, function or quality of life that result from care. Studies that assessed the effect on clinical outcomes were divided in two groups: (a) studies assessing the effect of less clinical consumption for equivalent clinical outcomes and (b) studies assessing the effect of CDSSs directly on clinical outcomes. No limitations were imposed with regard to language. The study types eligible for inclusion were randomized controlled trials, non-randomized controlled trials and before-and-after studies. Observational studies and studies without control groups were excluded.

2.5. Extraction and Assessment of Quality

Data was extracted using the Cochrane Collaboration’s double-data collection and extraction methodology [23]. The following data were retrieved by use of a structured data collection form: study year, study design, cancer type, system classification, system features, clinical topic addressed, outcome parameters, results, sample size, control and intervention group. Summative tables were created with descriptive comparison between the studies in outcomes and study characteristics. Due to heterogeneity of the data, meta-analyses was not possible. Outcomes were categorized in process outcomes, guideline adherence and clinical outcomes and analyzed per category. If studies evaluated more than one outcome category, the same study can be found in multiple tables. In addition, risk of bias for non-randomized studies and quality of evidence were graded by use of the ROBINS-I tool and GRADE scale [24,25].

3. Results

3.1. Eligible Studies

With the search strategy presented in Supplementary File 1, 13,919 records were identified. After removal of duplicates, 11,397 studies were selected for screening. After screening of title and abstracts, 61 full-text articles were assessed for eligibility and 9 studies were included in the final analysis. The PRISMA-P 2015 flowchart (Figure 1) provides more information about the literature selection process.

The percentage of inter-rater agreement during screening of title and abstract was 98.9% and during screening of full-text 95.1%.
3.2. Study Characteristics

Table 1 describes the characteristics of the included studies. All studies were conducted in adults (n = 7985; 78.8% female) in the United States (4/9) or Europe (5/9). Six studies were performed in a single center, two studies in multiple centers and for one study this was not defined in the article. Types of cancer included colorectal cancer (n = 245 individuals; 3.1% of total number of individuals in these studies), lung cancer (n = 2227; 27.8%), prostate cancer (n = 325; 4.1%), breast cancer (n = 5040; 63.1%) and other cancer types (n = 148; 1.9%). Clinical topics that were addressed by use of CDSSs are colony stimulating factor (CSF) support to manage chemotherapy-induced febrile neutropenia (2/9), treatment of tumor-induced pain (1/9), treatment decisions in multidisciplinary team (MDT) meetings (2/9), pain management (1/9), treatment planning (1/9) and follow-up based on carcino-embryonic antigen (CEA) testing (1/9). All studies targeted the physicians as users. Six studies targeted multiple specialisms; the others focused on one specialism. CDSSs of included studies focused on risk assessment or therapy options to support informed decisions [26–32], as well as statistical methods and data mining to generate patient-specific recommendations [33,34]. For most studies (7/9), clinical guidelines formed the knowledge base of the CDSS.
Table 1. Study Characteristics.

| Study                      | Study Design           | Cancer                  | System Classification | Clinical Topic                                      | Outcome Parameters                                      | Total Sample Size | Control (N = Number of Participants) | Intervention (N = Number of Participants) | Risk of Bias | Quality of Evidence |
|----------------------------|------------------------|-------------------------|-----------------------|-----------------------------------------------------|---------------------------------------------------------|-------------------|--------------------------------------|-------------------------------------------|-------------|---------------------|
| Adeboyeje et al., 2017 [26]| Multicenter, before-after, cohort study | Lung                    | Decision support system | CSF support for chemotherapy                        | (1) % CSF use (2) % at high risk for febrile neutropenia | 1857              | National guideline (N = 707)         | CDSS (N = 1150)                           | Serious      | Low                 |
| Agiro et al., 2018 [27]   | Multicenter, before-after, cohort study | Breast                  | Decision support system | CSF support for chemotherapy                        | (1) % CSF use (2) % at high risk for febrile neutropenia | 4001              | National guideline (N = 1991)        | CDSS (N = 2010)                           | Serious      | Low                 |
| Christ et al., 2018 [28]  | Single center, before-after, cohort study | Hematologic malignancies and solid tumors | Decision support system | Pain management of opioid-tolerant oncology patients | (1) Attainment of analgesia (2) Frequency medication (3) Frequency pain assessment (4) Guideline adherence (5) Pain score | 62                | National guidelines (N = 30)        | CDSS (N = 32)                             | Critical     | Very low            |
| Rios et al., 2003 [29]    | Before-after, cohort study | Breast and prostate     | CPG system            | Treatment planning                                  | Guideline adherence                                     | 907               | Standard of care (Breast N = 320, prostate N = 188) | CDSS (Breast N = 270, prostate N = 129) | Critical     | Very low            |
| Seroussi et al., 2007 [30]| Single center, before-after, cohort study | Breast                  | Decision support system | Treatment decisions by MDT                          | Guideline adherence                                     | 316               | MDT (N = 139)                        | MDT supported by CDSS (N = 177)           | Critical     | Very low            |
| Verberne et al., 2012 [31]| Single center, before-after, cohort study | Colorectal              | Decision support system | Follow-up based on CEA testing                     | (1) Workload clinicians for follow-up (2) % of metastases found at follow-up (3) % curative metastasectomy | 245               | Standard of care (N = 61)            | CDSS (N = 184)                           | Critical     | Very low            |
| Bouaud et al., 2003 [32]  | Single center, before-after, cohort study | Breast                  | CPG system            | Treatment decisions by MDT                          | (1) Treatment decision (2) Clinical trial inclusion rate (3) Compliance to CPG | 127               | MDT (N = 127)                        | MDT supported by CDSS (N = 127)           | Critical     | Very low            |
| Jackman et al., 2017 [33] | Single center, before-after, cohort study | Non-small cell lung     | Clinical pathway      | Treatment for stage IV                              | (1) Costs (2) Overall survival                          | 370               | Standard of care (N = 160)           | CDSS (N = 210)                           | Serious      | Low                 |
| Bertsche et al., 2009 [34]| Single center, before-after, cohort study | All types               | Decision support system | Treatment of tumor-induced-pain                     | (1) % deviation from guideline (2) Pain score           | 100               | Standard of care (N = 50)            | CDSS (N = 50)                            | Critical     | Very low            |

CSF = colony stimulating factor, CDSS = computerized clinical decision support system, CPG = clinical practice guidelines, MDT = multidisciplinary team, CEA = blood biomarker Carcino-Embryonic Antigen, *Number of centers is not mentioned.
3.3. Impact of CDSS on Oncology Practice

Tables 2–4 show an overview of the outcomes measured in the nine studies included in this systematic review.

3.3.1. Process Outcomes

Six studies reported process outcomes (Table 2). The issues addressed included: use of CSF to control chemotherapy-induced febrile neutropenia [26,27], physician-prescribing behavior [32], clinical trial rate [32], attainment of analgesia [28], time to analgesia [28], frequency of pharmaceutic intervention and pain assessment [28], costs [33] and workload [31]. Comparators included usual care, based on either MDT decisions or clinical guidelines.

Implementation of a CDSS was shown to positively impact the following process outcomes:

1. Use of CSF: Febrile neutropenia (FN) frequently complicates cancer chemotherapy; therefore CSF is often administered to reduce the risk and severity of FN. However, 30% of the patients that receive CSF have a low risk of FN, increasing costs and patient burden with no clinical benefit. Agiro et al. and Adeboyeje et al. showed that implementation of CDSSs significantly decreased the use of CSF as primary prevention for FN, which was interpreted as reduced overtreatment [26,27].

2. Physician-prescribing behavior: Bouaud et al. showed that initial decisions in breast cancer management were modified in 31% of cases after implementation of a CDSS. Whatever the motivation for change, it was always directed towards an improvement in patient management [32].

3. Frequency of pain assessment: Christ et al. showed that frequency of nursing pain assessments within 24 h after admission was significantly higher in the postimplementation group compared to the pre-implementation group (12.0 vs. 7.4 $p < 0.001$). Increased frequency of nursing pain assessment is associated with improved pain outcomes [28].

4. Healthcare costs: Jackman et al. suggests that the use of a CDSS resulted in a significant reduction in total costs for stage IV non-small cell lung cancer patients one year after diagnosis, by approximately $17,000 (from $69,122 before to $52,037) [33].

5. Clinician’s workload: Verberne et al. calculated that on average a clinician needs 64 min per patient per year in the follow-up of colorectal cancer (CRC). Clinicians’ workload was significantly reduced to 23 min per patient per year after implementation of the CDSS, saving more than 40 min per patient per year during follow-up [31].

No significant effects of implementation of a CDSS were found by Christ et al. and Bouaud et al. for the number of patients recruited for clinical trials, attainment of analgesia, time to analgesia and frequency of documented pharmaceutic interventions [28,32].

3.3.2. Guideline Adherence

Five studies assessed adherence to clinical practice guidelines (Table 3) [28–30,32,34]. Three studies showed improvement in guideline adherence in breast cancer management [29,30,32], two studies showed conflicting results in guideline adherence in pain management [28,34] and no significant difference in guideline adherence in prostate cancer management was reported [29].

Three studies reported a significant increase in adherence to breast cancer guidelines (Oncolor guidelines, Cancer Est) after implementation of a CDSS ranging from 9.3% to 24.1% [29,30,32]. Rios et al. suggested no significant effect of a CDSS on guideline adherence in prostate cancer management to CancerEst guideline recommendations.

Bertsche et al. showed a 60% reduction in number of deviations from pain management guidelines (WHO principles) [34]. In contrast, the study of Christ et al. showed no significant difference in compliance rate of pharmacist’s decisions to NCCN guidelines on pain regimes for oncology patients after implementation of a CDSS.
3.3.3. Clinical Outcomes

In total six studies assessed the effect of higher level CDSSs on clinical outcomes (Table 4).

Four studies assessed the effect of less clinical consumption for equivalent clinical outcomes [26,27,31,33]. Adeboyeje et al. showed a 9% reduction in CSF use in lung cancer management after implementation of a CDSS, while the FN rate did not change significantly [26]. Agiro et al. showed similar results for CSF use in breast cancer management [27]. Jackman et al. reported a significant decrease in the average 1-year costs of care after implementation of a clinical pathway for lung cancer, with no compromise in survival [33]. Last, Verberne et al. showed a reduction in clinicians’ workload after implementation of a CDSS for CRC management, with no significant difference in metastases found in follow-up [31].

Two studies assessed the effect of CDSSs directly on clinical outcomes, neither showed a significant effect of CDSSs on clinical outcomes. Bertsche et al. showed no significant change in pain intensity score (NVAS) on day 5 after admission, after implementation of a CDSS [34]. Similar, Christ et al. showed no significant difference in mean pain score at hospital admission and after 28 h [28].
### Table 2. Impact of CDSS on Process Outcomes.

| Study                        | Installation | System Features                                                                 | Key Outcomes Associated with CDSS                                                                 | Results (Control vs. Intervention)                                                                 |
|------------------------------|--------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------|
| Adeboyeje et al., 2017 [26]  | Web based    | CPG ¹-⁴ based, calculates febrile neutropenia risk and recommends CSF use       | Percentage CSF use based on febrile neutropenia risk assessment                                     | 48.4% vs. 35.6%, \( p = 0.001 \), 95% CI: −14.7 to −2.7                                      |
| Agiro et al., 2018 [27]      | Web based    | CPG ³-⁴ based, calculates febrile neutropenia risk and recommends CSF use       | Percentage CSF use based on febrile neutropenia risk assessment                                     | 74.9% vs. 68.5%, \( p = 0.006 \), 95% CI: −6.0 to −4.7                                      |
| Christ et al., 2018 [28]     | Integrated in EMR | CPG ³ based, identifies patients who require pain assessment, displays patient-specific information and the most recent and maximum pain score | (a) Attainment of analgesia (defined as a pain score ≤ 4) at 24 h from admission                   | (a) 33.3% vs. 43.8%, \( p = 0.78 \)                                                   |
|                              |              |                                                                                  | (b) Time to analgesia (hours)                                                                     | (b) 14 vs. 15.9, \( p = 0.59 \)                                                   |
|                              |              |                                                                                  | (c) Percentage of documented pharmacy intervention                                                | (c) Within first 24 h: 17.2% vs. 12.5%, \( p = 0.65 \). During entire admission: 31.0% vs. 56.3%, \( p = 0.32 \) |
|                              |              |                                                                                  | (d) Mean frequency of pain assessments in first 24 h                                              | (d) 7.4 vs. 12.0, \( p < 0.001 \)                                                   |
| Verberne et al., 2012 [31]   | Intranet-based | Assigns patients to one of three follow-up intervals based on CEA change, writes appropriate follow-up letter | (a) Working hour’s clinician for 5 years follow-up of a 200 patient cohort                       | (a) 1067 vs. 380                                                                   |
|                              |              |                                                                                  | (b) Median follow-up in years for CRC patients after completion of treatment                      | (b) 3.21 ((5% CI: 0.1 to 6.05) vs. 2.66 (95% CI: 0.2 to 10.8), \( p = 0.35 \) |
|                              |              |                                                                                  | (c) Number of outpatient clinical visits to the surgeon for follow-up                           | (c) 0 (95% CI: 0 to 7) vs. 3 (95% CI: 0 to 10), \( p < 0.001 \)                       |
| Bouaud et al., 2001 [32]     | Not mentioned | Hypertextual navigation in CPG * structured decision tree flowchart            | (a) Percentage change between initial and final MDT treatment decisions                           | (a) 31% (39/127) **                                                                 |
|                              |              |                                                                                  | (b) Percentage of patients recruited for clinical trials (initial vs. final)                     | (b) 6.3% vs. 9.4%, \( z = 1.13 \)                                                     |
| Jackman et al., 2017 [33]    | Web based    | Algorithms define the best fitting care pathway for patients at each point in care | Costs of care for 1 year after time of diagnosis in US dollar:                                     | (a) $69,122 (95% CI: 33,242 to 105,001) vs. $52,037 (95% CI: 25,200 to 84,849), \( p = 0.01 \) |
|                              |              |                                                                                  | (b) Adjusted costs                                                                             | (b) $64,508 (95% CI: 53,140 to 75,876) vs. $48,515 (95% CI: 41,421 to 55,608), \( p = 0.03 \) |
|                              |              |                                                                                  | (b) Unadjusted costs                                                                           |                                                                                       |

CPG = clinical practice guidelines, CSF = colony stimulating factor, MDT = multidisciplinary team, CEA = blood biomarker Carcino-Embryonic Antigen, CRC = colorectal cancer,¹ = ESMO clinical practice guidelines,² = EORTC guidelines,³ = NCCN guideline,⁴ = ASCO guideline, * Unknown origin, ** This outcome represents the comparison of initial and final therapeutic decisions.
Table 3. Impact of CDSS on Guideline Adherence.

| Study                  | Installation                      | System Features                                                                 | Key Outcomes Associated with CDSS                                                                 | Results (Control vs. Intervention)                                      |
|------------------------|-----------------------------------|---------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------|----------------------------------------------------------------------|
| Christ et al., 2018 [28] | Integrated in EMR                | CPG\(^1\) based, identifies patients who require pain assessment, displays patient-specific information and the most recent and maximum pain score | Percentage of guideline-adherent pain regimens                                                 | 40.0% vs. 46.9%, \(p = 0.97\)                                         |
| Rios et al., 2003 [29]  | Not mentioned                     | CPG\(^2\) based, organizes patient data and generates patient-specific recommendations | Percentage of guideline-adherent treatment decisions                                              | (a) 77.8% vs. 87.1%, \(p = 0.02\)                                    |
|                        |                                   |                                                                                  | (b) 86.7% vs. 89.9%, \(p = 0.35\)                                                              |                                                                      |
| Seroussi et al., 2007 [30] | Not mentioned                     | CPG\(^3\) based, contextualizes both guideline medical knowledge and patient information and generates patient-specific recommendations | Percentage of guideline-adherent treatment decisions                                             | 79.2% vs. 93.4%, \(p < 10^{-5}\)                                     |
| Bouaud et al., 2001 [32] | Not mentioned                     | Hyper textual navigation in CPG * structured decision tree flowchart            | Percentage of guideline-adherent treatment decisions                                             | 61.42% vs. 85.03%, \(p < 10^{-4}\)                                   |
| Bertsche et al., 2009 [34] | Integrated in hospital drug information system. | Algorithms based on CPG\(^4\) generate pain specific recommendations               | Percentages of deviations from guidelines                                                       | (a) 80% vs. 85%, \(p = 0.6\)                                         |
|                        |                                   |                                                                                  | (b) 74% vs. 14%, \(p < 0.001\)                                                                |                                                                      |

CPG = clinical practice guidelines, EMR = electronic medical record, \(^1\) = NCCN guideline, \(^2\) = Oncolor guideline, \(^3\) = CancerEst, \(^4\) = WHO principles for pain therapy, * Unknown origin.
Table 4. Impact of CDSS on Clinical Outcomes.

| Study                        | Installation                         | System Features                                                                 | Key Outcomes Associated with CDSS                                                                                                                                                                                                 | Results (Control vs. Intervention)                      |
|------------------------------|--------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|
| Adeboyeje et al., 2017 [26]  | Web based                            | CPG 1-4 based, calculates febrile neutropenia risk and recommends CSF use       | Percentage of patients at high risk for febrile neutropenia 2.8% vs. 4.3%, \( p = 0.927 \), 95% CI: -0.35 to 0.10                                                                                                                  |                                                         |
| Agiro et al., 2018 [27]      | Web based                            | CPG 3-4 based, calculates febrile neutropenia risk and recommends CSF use       | Percentage of patients at high risk for febrile neutropenia 5% vs. 5.5%, \( p = 0.778 \), 95% CI: -0.2 to 0.3                                                                                                                   |                                                         |
| Christ et al., 2018 [28]     | Integrated in EMR                   | CPG 3 based, identifies patients who require pain assessment, displays patient-specific information and the most recent and maximum pain score | (a) Mean pain score (NVAS) at hospital admission 6.3 vs. 7.4, \( p = 0.063 \)                                                                                                                                           | (a) Mean pain score (NVAS) over the first 28 h 4.9 vs. 4.2, \( p = 0.11 \) |
| Verberne et al., 2012 [31]   | Intranet-based                      | Assigns patients to one of three follow-up intervals based on CEA change, writes appropriate follow-up letter | (a) Percentage of metastases found in follow-up 13% vs. 9%, \( p = 0.06 \)                                                                                                                                            | (b) Percentage of curative metastasectomy for metastases found in follow-up 1.6% vs. 3.8%, \( p = 0.13 \) |
| Jackman et al., 2017 [33]    | Web based                            | Algorithms define the best fitting care pathway for patients at each point in care | (c) Median overall survival in months 10.7 vs. 11.2 (n = 210), \( p = 0.08 \)                                                                                                                                  |                                                         |
| Bertsche et al., 2009 [34]   | Integrated in hospital drug information system | CPG 5 based algorithms generate pain specific recommendations                      | Pain intensity score (NVAS) on day 5 after admission 2.4 vs. 2.0, \( p = 0.43 \)                                                                                                                                   | (a) At rest 4.0 vs. 4.0, \( p = 0.89 \) |

CPG = clinical practice guidelines, CSF = colony stimulating factor, CDSS = computerized clinical decision support system, NVAS = numeric visual analogue scale, CEA = blood biomarker Carcino-Embryonic Antigen, ¹ = ESMO clinical practice guideline, ² = EORTC guideline, ³ = NCCN guideline, ⁴ = ASCO guideline, ⁵ = WHO principles for pain therapy.
3.4. Risk of Bias and Level of Evidence

With use of the Robins-I tool, the risk of bias is rated critical in six [28–32,34] studies and serious in three studies [26,27,33]. An overview of the risk of bias scoring is provided in Figure 2.

Based on the GRADE scale, the level of evidence had to be rated low in three studies [26,27,33] and as very low in six studies [28–32,34].

| Study                          | Confounding | Selection of Participants | Classification of Interventions | Deviations of Interventions | Missing Data | Measurement of Outcomes | Selection in Reported Results | Overall Bias |
|--------------------------------|-------------|---------------------------|---------------------------------|----------------------------|--------------|------------------------|------------------------------|---------------|
| Adeboyeje et al. (2017)        | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Agiro et al. (2018)            | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Bertsche et al (2009)          | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Bouad et al. (2001)            | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Christ et al. (2018)           | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Jackman et al (2017)           | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Rios et al. (2003)             | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Séroussie et al. (2007)        | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |
| Verberne et al. (2012)         | ●           | ●                         | ●                               | ●                          | ●            | ●                      | ●                            | ●             |

- Low
- Moderate
- Serious
- Critical
- No Information

Figure 2. Risk of bias assessment.

4. Discussion

4.1. Summary of Evidence

We systematically reviewed scientific literature and identified the impact higher level CDSSs can bring to oncology clinical practice, operationalized in terms of process outcomes, guideline adherence and clinical outcomes. Overall, implementation of CDSSs resulted in significant improvements for process outcomes and guidelines adherence but no significant differences for clinical outcomes. However, all studies show a critical or serious risk of bias and a low to very low quality of evidence. While this review suggests benefits of higher level CDSS for oncology practice, there is the need for high-quality research.

4.2. Overall Completeness and Applicability of Evidence

The applicability of the evidence is limited due to several reasons. None of the included studies evaluated deviations from the intended CDSS use. However, literature shows that improper use of CDSSs did occur in other studies. Improper use can be defined as misusing the software or not using the software to its full capacity. Whereas proper use can be defined as correctly using the software by accurately processing and interpreting patient specific data [35,36]. An example of improper and proper use is given in previous research by Bouad et al. in which physicians’ attitudes towards the advice of a decision support system was explored [35]. This study evaluated the way a CDSS (Oncodoc2) was used and the impact of the system on MDT decision compliance with CPGs. Distinguished were proper use, decisions made with correct CPG navigations and improper use, decisions made with incorrect CPG navigations. In case of proper use, MDT navigations were identical to reference navigations and in case of improper use, MDT navigations differed from reference navigations. Reported was that
36.8% of the CPG navigations performed in Oncodoc2 were done improperly and 33.9% properly. The compliance rate was significantly different according to the quality of navigations; 94.2% for correct navigations, 80.0% for incorrect navigations and 90.2% for missing navigations as no decision support system was used [35]. Proper use of CDSSs is of major importance to ensure patient safety and to evaluate the effect of a CDSS. Bouaud et al. concluded that it was better not to use the CDSS than to use it improperly, as their results suggested improper use caused lower decision quality than not using the system [35]. Therefore, without detailed information on deviations from intended use the applicability of evidence is limited.

Moreover, in all studies the CDSSs are practiced in a specific clinical area within the oncology. Due to this, the generalizability of the results to other types of cancer or tests is limited. Changes in system features are probably necessary before results can be extrapolated to other cancer types and workflows. Additionally, except for two, all studies were performed in a single center setting. Further, several included studies lacked transparency in missing data. For example, Rios et al. included 39 patients but only 30 patients are reported in the results [29]. These missing data can result in an under- or overestimation of the reported effect.

Conflicting results were found for adherence to pain management guidelines. Bertsche et al. showed a 60% reduction in deviations from pain management guidelines [34], while Christ et al. found no significant difference in guideline adherence after implementation of a CDSS [28]. These conflicts may be explained by differences in guidelines (WHO principles, NCCN guidelines), study population and definition of guideline adherence.

4.3. Agreements and Disagreements with Literature

The majority of studies included in this review evaluated the impact of CDSSs on process outcomes in oncology care. This is in line with the review of Pawloski et al., which assessed the impact of CDSSs in oncology practice and described positive impacts on prescriber errors, safety events and workflow [11].

Outside the scope of oncology, several reviews reported positive effects of CDSSs on process outcomes. The review of Jia et al. assessed the effects of CDSSs on medication prescription, medication dose and other drug related outcomes [37]. This study reported that CDSSs significantly impact medication administration in 108 out 143 studies included [37]. The review of Bright et al. assessed CDSSs with a broad scope in healthcare [38]. Modest evidence is reported from academic and community inpatient and ambulatory settings, showing reduced hospitalization expenses with CDSS use and a positive effect on costs compared with control groups and other non-CDSS intervention groups [38]. No prior research and reviews evaluated the impact of CDSSs on workload. The reduction in clinicians’ workload reported by Verberne et al. should be confirmed in future research [31]. Similar, we found significant effects for drug administration, costs and workload. However, comparison with previous reviews is challenging since our results were reported specifically within oncology care.

Previous reviews demonstrated a positive impact of CDSSs, that can be interpreted as simple level, on guideline adherence in and outside oncology [11,39,40]. These findings are consistent with most of our results. All studies in this review showed a significant increase in guideline adherence, except for one study on CDSS in prostate cancer. The later was explained by Rios et al. as a result of less complex decision-making within prostate cancer management. Overall, results suggest that CDSSs can translate the complex data into clinical meaningful support and could ultimately result in less practice variation.

The effect of CDSSs on clinical outcomes is sparsely studied [8,41,42]. Previous reviews mainly focused on CDSSs that can be interpreted as simple level. They reported only a few studies that have positive benefits on patient outcomes. Lack of clinically important findings may be due to inappropriate study designs for measuring clinical outcomes. Mostly because of limited follow-up times and small sample sizes. These findings are in line with our results; two studies evaluated the
direct impact of CDSSs on clinical outcomes and showed no significant differences after implementation of a CDSS [28,34].

4.4. Strengths and Limitations

Our systematic review has several strengths. Over 10,000 articles were screened by two independent researchers following the PRISMA-P 2015 and the Cochrane Collaboration’s double-data collection and extraction methodology [13]. We are the first to specifically evaluate the impact of higher level CDSSs. By doing this, we expand the current landscape, complementary to the systematic review of Pawloski et al. [11].

Our review also has limitations. First, higher level CDSS may be misclassified as low level during the screening process due to limited or unclear information. Subsequently, exclusion of misclassified CDSSs cannot be rule out. Second, general observations on higher level CDSSs are limited due to small numbers of studies included and heterogeneity in interventions, populations, settings and outcomes. Third, we acknowledge that publication bias and selective reporting cannot be excluded. Finally, guided by the PRISMA-P 2015 we used the GRADE scale to rate the quality of evidence of the included studies. In the GRADE approach non-randomized studies can provide high quality of evidence but will automatically be downgraded for limitations in design such as lack of blinding [25]. In the evaluation of CDSSs a double blind design is not possible, as caregivers have to use the system. Therefore, even a well-designed RCT evaluating a CDSS will be rated low level of evidence. In conclusion, before discarding the results of CDSS evaluation, the level of evidence has to be taken into consideration carefully.

5. Future Research

Higher level CDSSs have the potential to significantly reduce workload, costs and to increase guideline adherence in clinical practice. To achieve this CDSSs need to contain one of the following features—automated CPGs, algorithms that define best fitting care pathways or algorithms based on CPGs. Additionally, CDSSs have to be web-based or integrated in the EMR and be able to manage big data including EMRs, disease registries, patient surveys and information exchanges. If these features are incorporated in higher level CDSSs, multiple facets of patient data can be used to optimize the diagnostic and therapeutic pathways of individual patients.

The reported significant effects of this review are based on studies rated with a low to very low quality of evidence and serious or critical risk of bias. Still, these outcomes demonstrate the potential value CDSSs can bring to oncology practice but also emphasizes the critical need for high quality studies. To ensure this quality, future research should include prospective analysis with appropriate study designs, for example, power analysis, long term follow-up and analytic methods that are necessary to demonstrate evidence-based improvements and to build the case for wider implementation.

6. Conclusions

The number of studies that evaluated impact of higher level CDSSs in oncology care is sparse. The reported evidence suggests that higher level CDSSs improve process outcomes and guidelines adherence. So far, no evidence was found for improved clinical outcomes. To further explore the impact of higher level CDSSs on the quality of care, high-quality research for reliable evidence is required.

Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/12/4/1032/s1,
Table S1: Search string.

Author Contributions: Conceptualization: M.P., J.J.F., J.P.M.S., M.T., H.H.A.W., S.E.K.; Methodology: H.H.A.W., S.E.K.; Formal analysis and Interpretation: H.H.A.W., S.E.K.; Writing – Original Draft Preparation: M.T., H.H.A.W., S.E.K.; Writing – Review & Editing: M.P., J.J.F., J.P.M.S., M.T., H.H.A.W., S.E.K.; Supervision: J.P.M.S., J.J.F., M.P., M.T.; Project Administration: H.H.A.W., S.E.K.; Funding Acquisition: None; Other: None. All authors have read and agreed to the published version of the manuscript.
Funding: This research did not receive any specific grant from funding agencies in the public, commercial or not-for-profit sectors.

Acknowledgments: The authors would like to thank all experts who provided input for our systematic review. Special thanks to OnYing Chan for her support in the development of our search strategy.

Conflicts of Interest: The authors declare no conflict of interest.

Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| ACM          | Association of Computing Machinery |
| ASCO         | American Society of Clinical Oncology |
| CDSS         | Clinical Decision Support System |
| CEA          | Carcino-Embryonic Antigen |
| CPG          | Clinical Practice Guidelines |
| CRC          | Colorectal Cancer |
| CSF          | Colony Stimulating Factor |
| EHR          | Electronic Health Record |
| EMR          | Electronic Medical Record |
| EORTC        | European Organisation for Research and Treatment of Cancer |
| ESMO         | European Society for Medical Oncology |
| FN           | Febrile Neutropenia |
| IEEE         | Institute of Electrical and Electronics Engineers |
| MDT          | Multidisciplinary Team |
| NCCN         | National Comprehensive Cancer Network |
| PRISMA-P     | Preferred Reporting Items for Systematic Reviews and Meta analyses Protocols |
| TRL          | Technology Readiness Level |
| VAS          | Visual Analogue Scale |
| WHO          | World Health Organisation |

References

1. Zugazagoitia, J.; Guedes, C.; Ponce, S.; Ferrer, I.; Molina-Pinelo, S.; Paz-Ares, L. Current Challenges in Cancer Treatment. *Clin. Ther.* 2016, 38, 1551–1566. [CrossRef] [PubMed]
2. Lunenfeld, B.; Stratton, P. The clinical consequences of an ageing world and preventive strategies. *Best Pract. Res. Clin. Obstet. Gynaecol.* 2013, 27, 643–659. [CrossRef] [PubMed]
3. Divo, M.J.; Martinez, C.H.; Mannino, D.M. Ageing and the epidemiology of multimorbidity. *Eur. Respir. J.* 2014, 44, 1055–1068. [CrossRef] [PubMed]
4. LeVasseur, N.; Fergusson, D.; Clemons, M. Unnecessary variation in practice: How to improve cancer care through pragmatic trials. *Curr. Oncol.* 2018, 25, e263–e264. [CrossRef] [PubMed]
5. Balogh, E.P.; Ganz, P.A.; Murphy, S.B.; Nass, S.J.; Ferrell, B.R.; Stovall, E. Patient-centered cancer treatment planning: Improving the quality of oncology care. Summary of an Institute of Medicine workshop. *Oncologist* 2011, 16, 1800–1805. [CrossRef] [PubMed]
6. Computer technology helps radiologists spot overlooked small breast cancers. *Oncology (Williston Park)* 2000, 14, 1450.
7. O’Sullivan, D.; Fraccaro, P.; Carson, E.; Weller, P. Decision time for clinical decision support systems. *Clin. Med. J. R. Coll. Physicians Lond.* 2014, 14, 338–341. [CrossRef]
8. Van de Velde, S.; Heselmans, A.; Delvaux, N.; Brandt, L.; Marco-Ruiz, L.; Spitaels, D.; Cloetens, H.; Kortteisto, T.; Roshanov, P.; Kunnamo, I.; et al. A systematic review of trials evaluating success factors of interventions with computerised clinical decision support. *Implement. Sci.* 2018, 13, 114. [CrossRef]
9. Roshanov, P.S. Features of effective computerised clinical decision support systems: Meta-regression of 162 randomised trials. *BMJ (Online)* 2013, 346, f657. [CrossRef]
10. Kawamoto, K.; Houlihan, C.A.; Balas, E.A.; Lobach, D.F. Improving clinical practice using clinical decision support systems: A systematic review of trials to identify features critical to success. *BMJ* 2005, 330, 765. [CrossRef]
11. Pawloski, P.A.; Brooks, G.A.; Nielsen, M.E.; Olson-Bullis, B.A. A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice. *J. Natl. Compr. Cancer Netw.* 2019, 17, 331–338. [CrossRef]

12. Klarenbeek, S.E.; Weekenstroo, H.H.A.; Sedelaar, J.P.M.; Fütterer, J.J.; Prokop, M.; Tummers, M. Effect of computerized clinical decision support systems on cancer care: A systematic review and meta-analysis. In *PROSPERO International Prospective Register of Systematic Reviews*; 2019; Available online: https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=124800 (accessed on 8 March 2019).

13. Moher, D.; Shamseer, L.; Clarke, M.; Ghersi, D.; Liberati, A.; Petticrew, M.; Shekelle, P.; Stewart, L.A. Preferred reporting items for systematic reviews and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst. Rev.* 2015, 1, 1. [CrossRef] [PubMed]

14. Révész, D.; Engelhardt, E.G.; Tamminga, J.J.; Schramel, F.M.; Onwuteaka-Philipsen, B.D.; Van De Garde, E.M.W.; Steyerberg, E.W.; Jansma, E.P.; De Vet, H.C.; Coupé, V.M. Decision support systems for incurable non-small cell lung cancer: A systematic review. *BMC Med. Inform. Decis. Mak.* 2017, 17, 144. [CrossRef] [PubMed]

15. Rahimi, R.; Kazemi, A.; Moghaddasi, H.; Rafsanjani, K.A.; Bahoush, G. Specifications of Computerized Provider Order Entry and Clinical Decision Support Systems for Cancer Patients Undergoing Chemotherapy: A Systematic Review. *Chemotherapy* 2018, 63, 162–171. [CrossRef] [PubMed]

16. O’Brien, M.A.; Whelan, T.J.; Villasis-Keever, M.; Gafni, A.; Charles, C.; Roberts, R.; Schiff, S.; Cai, W. Are cancer-related decision aids effective? A Systematic review and meta-analysis. *J. Clin. Oncol.* 2009, 27, 974–985. [CrossRef]

17. Ilic, D.; Jammal, W.; Chiarelli, P.; Gardiner, R.A.; Hughes, S.; Stefanovic, D.; Chambers, S.K. Assessing the effectiveness of decision AIDS in prostate cancer decision making: A systemic review. *Psycho Oncol.* 2015, 24, 1303–1315. [CrossRef]

18. Souza, N.M.; Sebaldt, R.J.; Mackay, J.A.; Prorok, J.C.; Weise-Kelly, L.; Navarro, T.; Wilczynski, N.L.; Haynes, R.B. Computerized clinical decision support systems for primary preventive care: A decision-maker-researcher partnership systematic review of effects on process of care and patient outcomes. *Implement. Sci.* 2011, 6, 87. [CrossRef]

19. Welch, B.M.; Kawamoto, K. Clinical decision support for genetically guided personalized medicine: A systematic review. *J Am Med Inform. Assoc.* 2013, 20, 388–400. [CrossRef]

20. Zhong, W.; Smith, B.; Haghhighi, K.; Mancuso, P. Systematic Review of Decision Aids for the Management of Men with Localized Prostate Cancer. *Urology* 2018, 114, 1–7. [CrossRef]

21. Ouzzani, M.; Hammady, H.; Fedorowicz, Z.; Elmagarmid, A. Rayyan-a web and mobile app for systematic reviews. *Syst. Rev.* 2016, 5, 210. [CrossRef]

22. Mankins, J.C. Technology readiness assessments: A retrospective. *Acta Astronaut.* 2009, 65, 1216–1223. [CrossRef]

23. Higgins, J.P.T.; Green, S.E. The Cochrane Collaboration. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* [updated March 2011]. 2011. Available online: www.handbook.cochrane.org (accessed on 15 December 2018).

24. Sterne, J.A.; Hernán, M.A.; Reeves, B.C.; Savović, J.; Berkman, N.D.; Viswanathan, M.; Henry, D.; Altman, D.G.; Ansari, M.T.; Boutron, I.; et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016, 355, i4919. [CrossRef] [PubMed]

25. Balsch, H.; Helfand, M.; Schünnemann, H.J.; Oxman, A.D.; Kunz, R.; Brozek, J.; Vist, G.E.; Falck-Ytter, Y.; Meerpohl, J.; Norris, S.; et al. GRADE guidelines: 3. Rating the quality of evidence. *J. Clin. Epidemiol.* 2011, 64, 401–406. [CrossRef] [PubMed]

26. Adeboyejo, G.; Agiro, A.; Malin, J.; Fisch, M.J.; DeVries, A. Reducing Overuse of Colony-Stimulating Factors in Patients With Lung Cancer Receiving Chemotherapy: Evidence From a Decision Support-Enabled Program. *J. Oncol. Pract.* 2017, 13, e337–e345. [CrossRef]

27. Agiro, A.; DeVries, A.; Malin, J.; Fisch, M.J. Real-world impact of a decision support tool on colony-stimulating factor use and chemotherapy-induced febrile neutropenia among patients with breast cancer. *J. Natl. Compr. Cancer Netw.* 2018, 16, 162–169. [CrossRef]

28. Christ, T.N.; Villadolid, J.J.; Choksi, A.; Malec, M.; Knoebel, R.W. Impact of a Clinical Decision Support Tool on Cancer Pain Management in Opioid-Tolerant Inpatients. *Hosp. Pharm.* 2018, 53, 256–262. [CrossRef]
29. Rios, M.; Desandes, E.; Bresson, B.; Lesur, I.K.A.; Boisson, F.; Demange, V.; Bey, P. Clinical practice guidelines in cancerology: Comparative study of three decision support-systems for breast and prostate cancer in Lorraine french region. *Bull. Cancer* 2003, 90, 363–370.

30. Séroussi, B.; Bouaud, J.; Gligorov, J.; Uzan, S. Supporting multidisciplinary staff meetings for guideline-based breast cancer management: A study with OncoDoc2. *AMIA Annu. Symp. Proc.* 2007, 2007, 656–660.

31. Verberne, C.J.; Nijboer, C.H.; de Boek, G.H.; Grossmann, I.; Wiggers, T.; Havenga, K. Evaluation of the use of decision-support software in carci-no-embryonic antigen (CEA)-based follow-up of patients with colorectal cancer. *BMC Med. Inform. Decis. Mak.* 2012, 12, 14. [CrossRef]

32. Bouaud, J.; Séroussi, B.; Antoine, E.C.; Zelek, L.; Spielmann, M. A before-after study using OncoDoc, a guideline-based decision support-system on breast cancer management: Impact upon physician prescribing behaviour. *Stud. Health Technol. Inform.* 2001, 84 Pt 1, 420–424.

33. Jackman, D.M.; Zhang, Y.; Dalby, C.; Nguyen, T.; Nagle, J.; Lydon, C.A.; Rabin, M.S.; McNiff, K.K.; Fraile, B.; Jacobson, J.O. Cost and Survival Analysis Before and After Implementation of Dana-Farber Clinical Pathways for Patients With Stage IV Non-Small-Cell Lung Cancer. *J. Oncol. Pract.* 2017, 13, e346–e352. [CrossRef]

34. Bertsche, T.; Askoxylakis, V.; Habi, G.; Laidig, F.; Schmitt, J.; Smitt, S.P.; Ghaderi, H.; Zabel-du Bois, A.; Milker-Zabel, S.; Debis, J.; et al. Multidisciplinary pain management based on a computerized clinical decision support system in cancer pain patients. *Pain* 2009, 147, 20–28. [CrossRef] [PubMed]

35. Bouaud, J.; Blaszka-Jaulerry, B.; Zelek, L.; Spano, J.P.; Lefranc, J.P.; Cojean-Zelek, I.; Durieux, A.; Tournigand, C.; Rousseau, A.; Séroussi, B. Health information technology: Use it well, or don’t! Findings from the use of a decision support system for breast cancer management. *AMIA Annu. Symp. Proc.* 2014, 2014, 315–324. [PubMed]

36. Bouaud, J.; Spano, J.P.; Lefranc, J.P.; Cojean-Zelek, I.; Blaszka-Jaulerry, B.; Zelek, L.; Durieux, A.; Tournigand, C.; Rousseau, A.; Vandenbussche, P.Y.; et al. Physicians’ Attitudes Towards the Advice of a Guideline-Based Decision Support System: A Case Study With OncoDoc2 in the Management of Breast Cancer Patients. *Stud. Health Technol. Inform.* 2015, 216, 264–269. [PubMed]

37. Jia, P.; Zhang, L.; Chen, J.; Zhao, P.; Zhang, M. The Effects of Clinical Decision Support Systems on Medication Safety: An Overview. *PLoS ONE* 2016, 11, e0167683. [CrossRef] [PubMed]

38. Bright, T.J.; Wong, A.; Dhurjati, R.; Bristow, E.; Bastian, L.; Coeytaux, R.R.; Samsa, G.; Hasselblad, V.; Williams, J.W.; Musty, M.D.; et al. Effect of computerized clinical decision-support systems: A systematic review. *Ann. Intern. Med.* 2012, 157, 29–43. [CrossRef] [PubMed]

39. Damiani, G.; Pinnarelli, L.; Colosimo, S.C.; Almiento, R.; Sicuro, L.; Galasso, R.; Sommella, L.; Ricciardi, W. The effectiveness of computerized clinical guidelines in the process of care: A systematic review. *BMC Health Serv. Res.* 2010, 10, 2. [CrossRef]

40. Chaudhry, B.; Wang, J.; Wu, S.; Maglione, M.; Mojica, W.; Roth, E.; Morton, S.C.; Shkelle, P.G. Systematic review: Impact of health information technology on quality, efficiency, and costs of medical care. *Ann. Intern. Med.* 2006, 144, 742–752. [CrossRef]

41. Garg, A.X.; Adhikari, N.K.; McDonald, H.; Rosas-Arellano, M.P.; Devereaux, P.J.; Beyene, J.; Sam, J.; Haynes, R.B. Effects of Computerized Clinical Decision Support Systems on Practitioner Performance and Patient Outcomes: A Systematic Review. *JAMA* 2005, 293, 1223–1238. [CrossRef]

42. Jaspers, M.W.; Smeulers, M.; Vermeulen, H.; Peute, L.W. Effects of clinical decision-support systems on practitioner performance and patient outcomes: A synthesis of high-quality systematic review findings. *J. Am. Med. Inform. Assoc.* 2011, 18, 327–334. [CrossRef]